Status:
UNKNOWN
Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Sensitivity
Eligibility:
All Genders
18-75 years
Brief Summary
Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
Eligibility Criteria
Inclusion
- 1\. Aged between 18 and 75 years;
- 2\. Lung adenocarcinoma;
- 3\. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
- 4 .The patient is able to understand and comply with the study and has provided written informed consent.
Exclusion
- 1\. Patients with a history of lung surgery;
- 2\. Postoperative pathology showed non-primary lung cancer;
- 3\. Patients with a history of other tumors;
- 4\. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
- 5\. Unable to cooperate with the researchers because of dementia or cognitive decline
- 6\. Other situations that are not in conformity with the standards and requirements of this trial.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05185544
Start Date
January 1 2022
End Date
December 31 2024
Last Update
January 11 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.